SCP0153
GLP-1 (Preproglucagon 72-107 amide) (GLP-1 human)
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Formule empirique (notation de Hill):
C184H273N51O57
Poids moléculaire :
4111.44
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.32
Produits recommandés
Pureté
≥95% (HPLC)
Forme
lyophilized
Composition
Peptide Content, ≥75%
Conditions de stockage
protect from light
Température de stockage
−20°C
Amino Acid Sequence
His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2
Application
GLP-1 (Preproglucagon 72-107 amide) (GLP-1 human) has been used to study its effect on vascular endothelial growth factor-A (VEGFA)-mediated endothelium-dependent signaling and vasodilation.
Glycogen-like peptide-1 (GLP-1) is an amino acid peptide derived from proglucogon. GLP-1 is involved in the regulation of the glycemic index via its affect on glucagon and insulin levels. GLP-1 may be used to study its interaction with its receptor, the GLP-1 receptor.
Actions biochimiques/physiologiques
Glycogen-like peptide-1 (GLP-1) is an insulinotropic hormone, which takes part in increasing insulin secretion and insulin sensitivity. It also inhibits the secretion of glycogen and reduces fasting glucose levels.
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Voglibose: an alpha-glucosidase inhibitor
Dabhi AS, et al.
Journal of Clinical and Diagnostic Research : JCDR, 7(12), 3023-3023 (2013)
GLP-1 inhibits VEGFA-mediated signaling in isolated human endothelial cells and VEGFA-induced dilation of rat mesenteric arteries
Egholm C, et al.
American Journal of Physiology. Heart and Circulatory Physiology, 311(5), H1214-H1224 (2016)
Alaa Al Helaili et al.
Biochemical and biophysical research communications, 533(1), 110-117 (2020-09-19)
Dysfunction of the gut-brain axis is one of the potential contributors to the pathophysiology of obesity and is therefore a potential target for treatment. Vagal afferents innervating the gut play an important role in controlling energy homeostasis. There is an
Fan Xiao et al.
Frontiers in cardiovascular medicine, 8, 709741-709741 (2021-09-14)
Objectives: This study explores the concentration and role of glucagon-like peptide-1 (GLP-1) in calcific aortic valve disease (CAVD). Background: Calcific aortic valve disease is a chronic disease presenting with aortic valve degeneration and mineralization. We hypothesized that the level of
Cecilie Egholm et al.
American journal of physiology. Heart and circulatory physiology, 311(5), H1214-H1224 (2016-11-03)
We investigated the acute effects of glucagon-like peptide-1 (GLP-1), GLP-1(1-36), and GLP-1(7-36) on vascular endothelial growth factor-A (VEGFA)-induced endothelium-dependent signaling and vasodilation. Our hypothesis was that GLP-1 released from intestinal l-cells modulates processes related to PLCγ activation, Src, and endothelial
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique